Form 4: Ironwood Pharmaceuticals Director Stock Grant

Mark G. Currie, a Director at Ironwood Pharmaceuticals Inc., received a grant of 63,481 shares of Class A Common Stock on June 16, 2026.

Summary

• Mark G. Currie, a Director of Ironwood Pharmaceuticals Inc., was granted 63,481 shares of Class A Common Stock on June 16, 2026.
• This grant is part of the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024.
• The restricted stock vests in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine stock grant to a director under an existing compensation plan and does not indicate significant new financial performance or strategic shifts.

Positives

• Director Mark G. Currie received a significant grant of 63,481 Class A Common Stock shares.
• The grant is made under an established compensation policy for non-employee directors.

Future Outlook

The restricted stock granted to Director Mark G. Currie vests in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.

Industry Context

StockSavvy.ai notes that this Form 4 filing details a standard stock grant to a non-employee director, a common practice in the pharmaceutical industry for aligning director incentives with shareholder value.

Corporate Governance

Related Party Transactions

• Grant of 63,481 Class A Common Stock shares to Director Mark G. Currie under the Non-employee Director Compensation Policy.

Stakeholder Impact

• Shareholders: The grant represents an issuance of equity, which is a form of compensation for directors. The vesting schedule aims to align director interests with long-term shareholder value.
• Employees: This filing does not directly impact employees but reflects standard corporate governance practices.
• Management: The filing is a routine disclosure related to director compensation.

Next Steps

• The granted restricted stock will vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.

Key Dates

Keywords

Ironwood Pharmaceuticals, IRWD, Form 4, Director Compensation, Stock Grant, Beneficial Ownership, SEC Filing